IL17A and rheumatoid arthritis: Furthermore, the pattern of IL-17+, IFNγ+ and IL-4+ CD4+T-lymphocytes production detected in new-onset DMARD-naïve RA patients could be modified by MTX treatment, and two different behaviors were identified in responders and nonresponders.